![]() Developpement d’inhibiteurs de cyclooxygénases: les analogues pyridiniques du nimésulideRenard, Jean-François ; Arslan, Deniz ; Garbacki, Nancy et alPoster (2009, May) Detailed reference viewed: 14 (4 ULg)![]() Nouveaux développements dans le domaine des analogues pyridiniques du nimésulide présentant un pont « inter-cycle » aminéRenard, Jean-François ; ; Pirotte, Bernard ![]() Poster (2006, June) Detailed reference viewed: 5 (0 ULg) The use of nimesulide and its analogues in cancer chemopreventionRenard, Jean-François ; ; et alin Anti-Cancer Agents in Medicinal Chemistry (2006), 6 Detailed reference viewed: 12 (1 ULg) Structure-based pharmacophore of COX-2 selective inhibitors and identification of original lead compounds from 3D database searching method; ; et al in European Journal of Medicinal Chemistry (2006), 41 Detailed reference viewed: 22 (0 ULg)![]() Développement de modulateurs de la voie du thromboxane A2 en tant qu’agents anti-angiogéniques et anti-métastatiques; ; et al Poster (2005, May) Detailed reference viewed: 8 (1 ULg) A new potential cyclooxygenase-2 inhibitor, pyridinic analogue of nimesulide; ; et al in European Journal of Medicinal Chemistry (2005), 40 Detailed reference viewed: 1 (1 ULg)![]() Pharmacophore generation to design new leads for selective cyclooxygenase-2 inhibition; ; et al Poster (2004, October 07) Detailed reference viewed: 5 (0 ULg) Modulation of the arachidonic cascade with omega 3 fatty acids or analogues: Potential therapeutic benefitsRoland, Isabelle ; ; Evrard, Brigitte et alin Mini-Reviews in Medicinal Chemistry (2004), 4(6), 659-668 Increasing interest in the role of omega 3 fatty acids has arisen in these latest years since evidence of their implication in the cardioprotective fish based diet of the Inuit has been demonstrated ... [more ▼] Increasing interest in the role of omega 3 fatty acids has arisen in these latest years since evidence of their implication in the cardioprotective fish based diet of the Inuit has been demonstrated. Furthermore, several in vitro, in vivo and epidemiological studies support the benefit of this fatty acids intake in various pathological states such as in the cardiovascular, cancer, inflammation, psychiatric, paediatric, pulmonary, dermatological and ophthalmologic fields. This review will focus on metabolism and pharmacological implication of w3 fatty acids intake as well as its interest in the prevention or treatment of the above-mentioned pathologies. [less ▲] Detailed reference viewed: 24 (5 ULg)![]() Identification d’inhibiteurs sélectifs de la cyclooxygénase-2 (COX-2); ; et al Conference (2004, June) Detailed reference viewed: 10 (0 ULg)![]() Identification d’un inhibiteur COX-2 sélectif », 18èmes Journées Franco-belges de Pharmacochimie; ; et al Poster (2004, June) Detailed reference viewed: 6 (0 ULg)![]() Synthèse et évaluation pharmacologique de nouveaux antagonistes du récepteur au thromboxane A2 dérivés du BM-573Hanson, Julien ; Renard, Jean-François ; et alPoster (2004, June) Detailed reference viewed: 5 (0 ULg)![]() Synthèse et évaluation pharmacologique d’analogues pyridiniques du nimésulide : variation du pont « inter-cycle; ; et al Poster (2004, June) Detailed reference viewed: 3 (0 ULg)![]() Development of thromboxane A2 modulators as promising anti-metastatic and anti-angiogenic compounds; ; et al Conference (2004, May) Detailed reference viewed: 2 (0 ULg) Effects of COX-2 inhibitors on ROS produced by Chlamydia pneumoniae-primed human promonocytic cells (THP-1)Mouithys-Mickalad, Ange ; Deby, Ginette ; Dogné, Jean-Michel et alin Biochemical and Biophysical Research Communications (2004), 325(4), 1122-1130 Chronic inflammation through foam cells and macrophages is important in atherosclerosis development, and can be considered as therapeutic targets. Cyclooxygenase and NADPH-oxidase were expressed within ... [more ▼] Chronic inflammation through foam cells and macrophages is important in atherosclerosis development, and can be considered as therapeutic targets. Cyclooxygenase and NADPH-oxidase were expressed within atherosclerotic lesions. Reactive oxygen species produced by NADPH oxidase were found to trigger the cyclooxygenase-2 expression. The effects of preferential COX-2 inhibitors on ROS produced by Chlamydia-primed human monocytes (THP-1 cells) were evaluated by fluorescence, chemiluminescence, oxymetry, and EPR spin trapping. Fluorescence assays showed an increased production of ROS with Chlamydia versus cells primed by 10(-8) M PMA. COX-2 inhibitors inhibited in a dose-dependent manner the luminol-enhanced CL while ibuprofen and diclofenac increased the chemiluminescence response. By EPR spin trapping, COX-2 inhibitors, ibuprofen, and diclofenac, exhibited a dose-dependent inhibiting effect (10 and 100 muM) on the EPR signal appearance. Our cell model combining EPR, chemiluminescence, and oxymetry appeared relevant to study the modulating effects of preferential COX-2 inhibitors on the cell oxidant activity and chronic inflammatory diseases. (C) 2004 Elsevier Inc. All rights reserved. [less ▲] Detailed reference viewed: 115 (36 ULg) New developments on thromboxane and prostacyclin modulators. Part II: prostacyclin modulators; Hanson, Julien ; David, Jean-Louis et alin Current Medicinal Chemistry (2004), 11 Detailed reference viewed: 18 (1 ULg) First and second generations of COX-2 selective inhibitors; ; et al in Mini Reviews in Medicinal Chemistry (2004), 4 Detailed reference viewed: 19 (3 ULg) Characterization of preferential activity on platelet thromboxane A2 receptors of BM-613, a new thromboxane A2 antagonistHanson, Julien ; ; et alin Fundamental & Clinical Pharmacology (2004) Detailed reference viewed: 3 (1 ULg) Modulation of the arachidonic cascade with omega3 fatty acids or analogues: potential therapeutic benefitsRoland, Isabelle ; ; Evrard, Brigitte et alin Mini Reviews in Medicinal Chemistry (2004), 4 Detailed reference viewed: 13 (3 ULg) New developments on thromboxane and prostacyclin modulators. Part I: thromboxane modulatorsDogné, Jean-Michel ; ; Hanson, Julien et alin Current Medicinal Chemistry (2004), 11 Detailed reference viewed: 17 (2 ULg) Progress in the field of GPIIb/IIIa antagonistsHanson, Julien ; ; David, Jean-Louis et alin Current Medicinal Chemistry - Cardiovascular and Hematological Agents (2004), 2 Detailed reference viewed: 13 (0 ULg) |
||